CCR8 antagonist 1

CAS No. 723304-76-5

CCR8 antagonist 1( LUN04765 )

Catalog No. M29004 CAS No. 723304-76-5

CCR8 antagonist 1 is an antagonist of C-C Motif Chemokine Receptor 8 (CCR8) with a Ki value of 1.6 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 114 Get Quote
5MG 192 Get Quote
10MG 282 Get Quote
25MG 480 Get Quote
50MG 691 Get Quote
100MG 972 Get Quote
500MG 1944 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    CCR8 antagonist 1
  • Note
    Research use only, not for human use.
  • Brief Description
    CCR8 antagonist 1 is an antagonist of C-C Motif Chemokine Receptor 8 (CCR8) with a Ki value of 1.6 nM.
  • Description
    CCR8 antagonist 1 is an antagonist of C-C Motif Chemokine Receptor 8 (CCR8) with a Ki value of 1.6 nM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    LUN04765
  • Pathway
    Autophagy
  • Target
    CCR
  • Recptor
    CCR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    723304-76-5
  • Formula Weight
    495.59
  • Molecular Formula
    C26H29N3O5S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 25 mg/mL (50.44 mM)
  • SMILES
    O=C(OCC)N1CCC(NS(=O)(=O)C2=CC=C(NC(=O)C=3C=CC=CC3C)C=4C=CC=CC42)CC1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Bindarit

    Bindarit exhibits selective inhibition against monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7 and MCP-2/CCL8.

  • Manninotriose

    Manninotriose has the pharmacological activities, such as promoting the proliferation of hematopoietic cells, improving immunity, lowering blood glucose and anti-tumor.

  • CCR6 antagonist 1

    CCR6 antagonist 1, a chemical compound acting as a CCR6 antagonist, effectively inhibits the CCL20/CCR6 axis. Its utility lies in research focused on autoimmune-mediated inflammatory diseases, including inflammatory bowel diseases (IBDs).